Copyright
©The Author(s) 2005.
World J Gastroenterol. Jul 28, 2005; 11(28): 4300-4304
Published online Jul 28, 2005. doi: 10.3748/wjg.v11.i28.4300
Published online Jul 28, 2005. doi: 10.3748/wjg.v11.i28.4300
Table 1 Clinical characteristics of stage IV gastrointestinal cancer
linical characteristics | Gastric cancer | Colorectal cancer | ||
X group | C group | X group | C group | |
ale/female | 21/11 | 17/12 | 19/16 | 23/12 |
ge: mean (range/yr) | 63.6 (3683) | 61.0 (3380) | 62.9 (4575) | 60.8 (3474) |
ecurrence (%) | 14 (43.8) | 14 (48.3) | 8 (22.9) | 9 (25.7) |
etastasis | ||||
iver (%) | 17 (53.1) | 16 (55.2) | 21 (60.0) | 22 (62.9) |
ung (%) | 8 (25.0) | 7 (24.1) | 11 (31.4) | 10 (28.6) |
eliac lymph node (%) | 21 (65.6) | 21 (72.4) | 14 (40.0) | 15 (42.9) |
thers (%) | 8 (25.0) | 9 (31.0) | 12 (34.3) | 10 (28.6) |
revious chemotherapy | 23 (71.9) | 22 (75.9) | 17 (48.6) | 19 (54.3) |
Table 2 Different chemotherapeutic effect of gastrointestinal cancers
Therapeutic effect | Gastric cancer | Colorectal cancer | Total | |||
X group | C group | X group | C group | X group | C group | |
n | 24 | 25 | 31 | 34 | 55 | 59 |
CR (n) | 1 | 1 | 1 | 0 | 2 | 1 |
PR (n) | 13 | 10 | 14 | 14 | 27 | 24 |
NC (n) | 5 | 10 | 12 | 14 | 17 | 24 |
PD (n) | 5 | 4 | 4 | 6 | 9 | 10 |
CR+PR (n) | 14 | 11 | 17 | 14 | 29 | 25 |
(%) | 58.3 | 44.0 | 54.8 | 41.2 | 52.7 | 42.4 |
TTP (mo) | 7.0±1.3a | 5.4±0.9 | 7.8±1.9a | 6.7±2.0 | 7.4±1.7a | 6.0±1.5 |
1-yr survival (%) | 41.7a | 36.0 | 64.5a | 52.9 | 53.1a | 44.5 |
Table 3 Chemotherapeutic side effects of gastrointestinal cancers (n)
Side effects | X group (n = 55) | C group (n = 59) | ||||||
I | II | III | IV | I | II | III | IV | |
Leukopenia | 21 | 8 | 5 | 0 | 20 | 8 | 4 | 0 |
Thrombocytopenia | 10 | 5 | 1 | 0 | 13 | 4 | 2 | 0 |
Nausea | 15 | 19 | 10 | 2 | 16 | 20 | 11 | 2 |
Vomiting | 11 | 11 | 4 | 1 | 14 | 12 | 3 | 2 |
Diarrhea | 7 | 9 | 3 | 0 | 5 | 6 | 2 | 0 |
HFS | 32 | 2 | 1 | 0 | 8 | 2 | 0 | 0 |
Neurotoxicity | 12 | 11 | 0 | 0 | 14 | 12 | 1 | 0 |
Table 4 Chemotherapeutic DI of gastrointestinal cancers, mg/(m2×wk)
Table 5 The average cost per patient of two groups (mean±SD, ¥, US $)
Group | Hospitalization(d) | Cost of drug | Other cost | Total cost | |||
¥ | US $ | ¥ | US $ | ¥ | US $ | ||
X | 5.94±3.11a | 7887.33±140.92a | 950.28±16.98a | 1250.02±101.43a | 150.60±12.22a | 9137.35±121.18 | 1100.89±14.60 |
C | 9.37±2.73 | 6108.97±205.44 | 736.02±24.75 | 2 852.75±217.73 | 343.70±26.23 | 8961.72±211.59 | 1 079.73±25.50 |
Table 6 Comparison of cost-effectiveness of two groups
- Citation: Fan L, Liu WC, Zhang YJ, Ren J, Pan BR, Liu DH, Chen Y, Yu ZC. Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies. World J Gastroenterol 2005; 11(28): 4300-4304
- URL: https://www.wjgnet.com/1007-9327/full/v11/i28/4300.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i28.4300